Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-339

Legacy effect can only affect half of patients max
and since there was no difference between drug and placebo in the 14 low protein patients, then legacy effect can only affect half of 26 patients theoretically...

anyway, outside of specific patient speculation, if there was a clear legacy effect, it’s very fast to show by just plotting all the individual patients in the subgroups for us. Takes very little time and effort. They took the time to plot some of this select info to show us but not all the patients and the two arms which they definitely have on hand.
since they chose not to share plots with all patients and which arms they were in (which would have prevented a lot of chaos on Monday), I’m betting it’s not as simple as a nice legacy effect

also I’m concerned that FSGS data has as been out for like 7 weeks. It’s only 7 eligible patients for analysis. Again, why aren’t they sharing that data? I have concerns in that trial that most patients may not show a clinically meaningful reduction of protein or they would have definitely made that a key point in their presentations. Instead they just say 2 patients have over 40% reduction, and 4 have SOME reduction

but anyway, good luck to all! I will definitely be watching along

and I genuinely do hope for the best for you all